gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CTKBHealthcareLab Analytical Instruments

Cytek Biosciences, Inc. Common Stock (CTKB)

$5.88−1.34%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$5.88▲ 50.38% in range
Nov 4, 2025Low $3.35 · High $6.30Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Cytek Biosciences closed at $5.88 on Nov 4, down 1.34%, 6.7% below its 52-week closing high. Volume of 1.6M shares was 1.14× its 20-day average (close to normal).

Split-adjusted performance: +9.3% over one month, +19.0% over six months, +49.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $48.14M, up 5.6% from a year earlier, with a net margin of -25.3%.

Short interest was 4.4M shares at the Oct 15 settlement, down 15.5% from the prior report (3.8% of float, 2.7 days to cover).

Market cap$764.3M130.0M shares
Revenue · quarter$48.1M+5.6% YoY
Diluted EPS$-0.09—
P/E · TTM—P/S 3.7×
Net margin-25.3%Gross 58.9%
Dividend yieldNone
52-week range3.35 – 6.30−6.7% from high
Volume1.6M1.14× 20-day avg
Volatility · 60d50.4%Annualised
Short % of float3.8%2.7 days to cover
Net cash$261.8MCash $262.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.2%1M +9.3%3M +41.3%6M +19.0%YTD +16.4%1Y +49.2%3Y +43.4%5Y −74.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum40
Revenue growth58
Net margin48
Value (low P/E)—
Size48

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short4.4M−15.5% vs prior
Days to cover2.7Settled Oct 15
% of float3.8%
Short vol. 10d37.7%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CTKBCytek Biosciences$5.88−1.34%+19.0%+5.6%−25.3%—$764.3M
PACBPacific Biosciences of California$2.55+4.51%+49.1%−1.9%−114.7%—$792.6MCompare
MASS908 Devices$11.07+3.75%+37.3%+23.3%−74.0%—$457.6MCompare
ALMRAlamar Biosciences$27.39−9.36%——−44.9%—$1.90BCompare
NAUTNautilus Biotechnolgy$2.29−2.55%−22.1%—−6682.1%—$291.7MCompare
QTRXQuanterix$3.04+3.40%−7.6%+34.4%−148.7%—$143.8MCompare
SEERSeer$1.70−1.73%−10.1%−23.4%−544.8%—$94.1MCompare
TXG10x Genomics$67.52+3.42%+196.9%−12.6%−11.9%—$8.80BCompare
BRKRBruker$63.79+12.90%+50.8%+5.2%−7.5%—$9.72BCompare

News about Cytek Biosciences

All news →
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out forZacks Investment Research · Oct 28, 2026▼ NegativeCytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026GlobeNewswire Inc. · Jun 2, 2026▲ PositiveCytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional ImpactGlobeNewswire Inc. · Mar 9, 2026▲ Positive

Quick answers

What does Cytek Biosciences do?
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors.
What is CTKB's market cap?
$764.30M, based on the Nov 4 close of $5.88.
Does Cytek Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CTKB is sold short?
4.4M shares, 3.8% of float, as of Oct 15, 2026.
What sector is CTKB in?
Healthcare, in the Lab Analytical Instruments industry.

About Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

HQ: Fremont, CA702 employeesListed Jul 23, 2021cytekbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology